-
Conivaptan, sold
under the
brand name Vaprisol, is a non-peptide
inhibitor of the
receptor for anti-diuretic hormone, also
called vasopressin. It was approved...
-
receptor antagonists and
include conivaptan, tolvaptan, demeclocycline, and
mozavaptan (OPC-31260), as well as lithium.
Conivaptan hydrochloride and tolvaptan...
-
protein intake. The
vasopressin receptor 2 antagonists,
tolvaptan or
conivaptan, may also be used. The
presence of
cerebral edema, or
other moderate to...
- (November 20, 2006). "Neue
Wirkstoffe -
Conivaptan". Österreichische
Apothekerzeitung (in German) (24/2006). "
Conivaptan hydrochloride".
Molecule of the Month...
-
clinical use or in
clinical trials as of 2009.
Unselective (mixed V1A/V2)
Conivaptan V1A
selective (V1RA)
Relcovaptan V1B
selective (V3RA)
Nelivaptan V2 selective...
-
tentative evidence that
vasopressin receptor antagonists (vaptans), such as
conivaptan, may be
slightly more
effective than
fluid restriction in
those with high...
- relative.
Vasopressin receptor antagonists can also
treat heart failure.
Conivaptan is the
first medication approved by the US Food and Drug Administration...
- (argipressin)
Vasotocin (argiprestocin) Antagonists:
Atosiban Balovaptan Conivaptan FR-218944 JNJ-17079166 JNJ-17308616 LIT-001 LY-307174 PF-184563 Relcovaptan...
- (argipressin)
Vasotocin (argiprestocin) Antagonists:
Atosiban Balovaptan Conivaptan FR-218944 JNJ-17079166 JNJ-17308616 LIT-001 LY-307174 PF-184563 Relcovaptan...
-
pancreatic cancer –
marketed with Hoffmann-La
Roche (Genentech).
Vaprisol (
conivaptan) –
Hyponatremia Veozah (fezolinetant) - Hot
Flashes (vasomotor symptoms)...
